Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBTXR3 with Radiation in Prostate Cancer
NCT02805894Phase 2Terminated
- Sponsor
- Nanobiotix
- Start
- Nov 2017
- Primary completion
- Mar 2020
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of NBTXR3 in prostate adenocarcinoma (2 arms), sponsored by Nanobiotix. Primary endpoints: Maximum Tolerated Dose and early Dose Limiting Toxicities (DLT) of NBTXR3 at 24 months and Recommended Dose(s) of NBTXR3 at 24 months. Started Nov 2017; status: terminated.
02
Drugs
NBTXR3
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT02805894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02805894.